Literature DB >> 15886797

Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada - is it necessary to define a new upper reference range for factor VIII?

Philip S Wells1, Nicole J Langlois, Marc A Webster, James Jaffey, Josdalyne A Anderson.   

Abstract

Previous studies suggest elevated factor VIII is a common, independent risk factor for venous thromboembolism (VTE); however, these studies included secondary and idiopathic VTE. We sought to explore the association between elevated factor VIII and VTE in Canadian patients with idiopathic thrombosis, and confirm the current upper factor VIII reference range was appropriate. We enrolled 300 consecutive patients with idiopathic VTE who were matched to friend controls by age, sex and ethnicity. Factor VIII levels were measured and compared between cases and controls. The optimal cut-off value to designate factor VIII levels as elevated was determined using a variety of methods. The optimal upper cut-off value for factor VIII levels was 270 IU/dl. In the logistic regression analysis, cases were more likely to have elevated factor VIII levels (OR:8.76), as were females (OR:1.93) and older subjects (OR: 1.05). Factor VIII cutoffs for a 95% specificity by age were 238 IU/dl for subjects <40 years, 248 IU/dl age 40-55 years, 261 IU/dl age 56-70 years, and 313 IU/dl age >70. Our findings confirm that elevated factor VIII is associated with an increased risk of idiopathic VTE. In our patients and matched controls, the current upper limit of normal (150 IU/dl) for factor VIII is not of clinical use. We propose that the upper limit be increased to 270 IU/dl or individual labs should establish their upper limit if they wish their assays to be discriminatory in patients with VTE. Age specific cut-offs may be clinically relevant.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15886797     DOI: 10.1160/TH05-01-0013

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  13 in total

1.  A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.

Authors:  Kevin R Viel; Deepa K Machiah; Diane M Warren; Manana Khachidze; Alfonso Buil; Karl Fernstrom; Juan C Souto; Juan M Peralta; Todd Smith; John Blangero; Sandra Porter; Stephen T Warren; Jordi Fontcuberta; Jose M Soria; W Dana Flanders; Laura Almasy; Tom E Howard
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

2.  Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease.

Authors:  Laura H Bukkems; Jessica M Heijdra; Nico C B de Jager; Hendrika C A M Hazendonk; Karin Fijnvandraat; Karina Meijer; Jeroen C J Eikenboom; Britta A P Laros-van Gorkom; Frank W G Leebeek; Marjon H Cnossen; Ron A A Mathôt
Journal:  Blood Adv       Date:  2021-03-09

3.  Cerebral venous thrombosis and plasma concentrations of factor VIII and von Willebrand factor: a case control study.

Authors:  Jean-Marc Bugnicourt; Bertrand Roussel; Blaise Tramier; Chantal Lamy; Olivier Godefroy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-22       Impact factor: 10.154

Review 4.  Management of venous thromboembolism in the elderly.

Authors:  Alex C Spyropoulos; Geno Merli
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 5.  Epidemiology of venous thromboembolism.

Authors:  John A Heit
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

6.  Quantification of perioperative changes in von Willebrand factor and factor VIII during elective orthopaedic surgery in normal individuals.

Authors:  A Kahlon; J Grabell; A Tuttle; D Engen; W Hopman; D Lillicrap; P James
Journal:  Haemophilia       Date:  2013-05-28       Impact factor: 4.287

7.  A pilot study to assess the feasibility of a multicenter cluster randomized trial for the management of asymptomatic persons with a thrombophilia.

Authors:  Philip S Wells; Martha L Louzada; Monica Taljaard; David R Anderson; Susan R Kahn; Nicole J Langlois; Julie Rutberg; Michael J Kovacs; Marc A Rodger
Journal:  J Genet Couns       Date:  2009-06-03       Impact factor: 2.537

Review 8.  Antithrombotic prophylaxis in patients with von Willebrand disease undergoing major surgery: when is it necessary?

Authors:  Massimo Franchini; Giovanni Targher; Martina Montagnana; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2008-08-14       Impact factor: 2.300

Review 9.  Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

10.  Recurrent myocardial infarctions in a young football player secondary to thrombophilia, associated with elevated factor VIII activity.

Authors:  Thomas P Vacek; Shipeng Yu; Shahnaz Rehman; Blair P Grubb; Daniel Kosinski; Cherian Verghese; Ehab A Eltahawy; Qaiser Shafiq
Journal:  Int Med Case Rep J       Date:  2014-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.